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Abstract: Latrodectism or envenomation by widow-spiders is common and clinically significant
worldwide. Alpha-latrotoxin is the mammalian-specific toxin in the venom that results in toxic effects
observed in humans. Symptoms may be incapacitating and include severe pain that can persist for
days. The management of mild to moderate latrodectism is primarily supportive while severe cases
have variously been treated with intravenous calcium, muscle relaxants, widow-spider antivenom
and analgesic opioids. The object of this systematic review is to examine the literature on the clinical
effectiveness of past and current treatments for latrodectism. MEDLINE, EMBASE and Google
Scholar were searched from 1946 to December 2016 to identify clinical studies on the treatment of
latrodectism. Studies older than 40 years and not in English were not reviewed. There were only
two full-publications and one abstract of placebo-controlled randomised trials on antivenom use for
latrodectism. Another two randomised comparative trials compared the route of administration of
antivenom for latrodectism. There were fourteen case series (including two abstracts), fourteen case
reports and one letter investigating drug treatments for latrodectism with the majority of these also
including antivenom for severe latrodectism. Antivenom with opioid analgesia is often the major
treatment reported for latrodectism however; recent high quality evidence has cast doubt on the
clinical effectiveness of this combination and suggests that other treatments need to be investigated.
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1. Introduction
Latrodectism or envenomation by widow-spiders (Latrodectus spp.), is common worldwide and
is the most clinically significant spider envenomation in the United States [1–3] and Australia [4,5].
Throughout the world, there are over 40 species of widow-spider, with the red-back spider (Latrodectus
hasselti) [6] in Australia and the black widow spider (various Latrodectus spp.) in the United States
of America [7] being of most clinical concern. However, species are found on all continents except
Antarctica. The venom contains alpha-latrotoxin (α-LTX), a mammalian-specific neurotoxin that binds
to presynaptic nerve terminals and stimulates massive neurotransmitter release Two classes of receptors
for α-latrotoxin have been identified. Neurexins are brain-specific proteins that partly function as cell
adhesion molecules binding α-latrotoxin in a Ca2+ dependent manner. CLs (CIRLs and latrophilins)
are not brain-specific but widely expressed in all tissues and bind α-latrotoxin independently of
Ca2+ [8,9]. Khvotchev and Südhof recently showed that α-latrotoxin inserts into the presynaptic
plasma membrane after receptor binding, resulting in an intracellular location of the N-terminal
sequences triggering neurotransmitter release [10]. Alpha-latrotoxin is most likely responsible for the
Toxins 2017, 9, 148; doi:10.3390/toxins9040148 www.mdpi.com/journal/toxins
Toxins 2017, 9, 148 2 of 20
majority of the clinical effects of latrodectism. Envenomation by the Latrodectus species can result in an
incapacitating syndrome of severe local, regional or systemic pain and autonomic features that, if left
untreated, may last for several days. Severe and persistent pain occurs in a half to two-thirds of cases
of latrodectism [11] and is the primary target of treatments. Treatment has ranged from intravenous
injection of calcium gluconate to muscle relaxants such as benzodiazepines with opioid analgesia to
specific treatment with antivenom, such as red-back spider antivenom (RBSAV, purified IgG-F(ab)2)
and black widow spider antivenom (whole IgG L. mactans). There continues to be concern regarding
the risk of acute severe allergic reactions and serum sickness with antivenom use, and adverse drug
effects with the use of benzodiazepines and opioids. The aim of this review is to examine the literature
on the effectiveness of clinical treatments for latrodectism.
2. Clinical Characteristics of Latrodectism
Symptoms of latrodectism are mediated by the neurotoxin alpha-latrotoxin. Latrotoxin causes
neurotransmitter release through both calcium-dependent (Neurexins) and calcium-independent
(latrophilin) mechanisms [8,9]. This results in skeletal muscle and autonomic effects. However, the most
troublesome and predominant feature of systemic latrodectism is local and regional pain, which classically
increases over hours. In Australia, local pain radiating up the bitten limb or from the bite site is typical,
whereas in North and South America back and abdominal pain predominate [5].The pain is accompanied
with nonspecific systemic effects such as nausea, vomiting, headache, malaise and lethargy, local and
regional diaphoresis, and less commonly other autonomic neurological effects [5,11]. Diaphoresis often
occurs in unusual patterns that are almost pathognomonic for latrodectism—Diaphoresis localised to the
bite site, bilateral below-knee diaphoresis, and asymmetrical regional diaphoresis are some characteristic
patterns. Nonspecific systemic effects occur in approximately one-third of the cases. Hypertension,
agitation, fever, priapism, patchy paralysis, paraesthesia, muscle fasciculations, and cardiac effects less
common [11].While the severity and some features of latrodectism vary for different widow spiders
from different regions, [1,4,11,12] pain is the most prominent feature in all cases. Early control of
pain is paramount as nociception elicits important physiological responses and reduction of pain can
improve clinical outcomes and prevent chronic pain [13].
3. Earlier Treatments for Latrodectism
Throughout most of the 20th century (particularly in North America) calcium was considered
a first-line treatment for latrodectism even though there have been no placebo-controlled clinical
trials to demonstrate its effectiveness [14].Indeed, calcium was once proposed as an “antidote” for
alpha-latrotoxin by virtue of its proposed efficacy in vitro [15].However, subsequent clinical experience
has suggested that calcium may not have the same effect clinically, resulting in a loss of confidence in
its effectiveness [1].
Five case series and one case report were identified investigating the treatment of latrodectism
with drug treatments such as calcium gluconate, muscle relaxants and opioid analgesia in the past
40 years. These are summarized in (Table 1), with study design problems identified. A more detailed
summation on some of these studies follows.
The earliest study reviewed was a case series by Key in 1981 [16]. Calcium gluconate and
methocarbamol, a muscle relaxant, were compared using an algorithmic treatment protocol on all
cases of Latrodectus (black-widow) envenomation seen over a period of three years. According to
the treatment algorithms, patients received calcium gluconate alone or after methocarbamol failure.
Six of 13 patients treated according to this algorithm were assessed as effectively treated by the
attending physician. Ten patients were treated with methocarbamol alone or after calcium gluconate
failure according to the second protocol. One of these patients was assessed as effectively treated.
Key concluded that calcium gluconate should remain the treatment of first-choice.
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Table 1. Summary of non-randomised clinical studies for latrodectism using earlier/alternate treatments.
Study Author/s Type of Study N Study Arms Efficacy Outcome Design Problems Study Conclusion/s
Key, 1981 [16]
Prospective
observational study,
with cross over to the
alternative treatment
with treatment failure
13/10 calcium gluconate vs. methocarbamol Not specified Small study
Calcium gluconate should
remain the treatment of first
choice for latrodectism as it had
a better outcome than
methocarbamol
Ryan, 1984 [17] Retrospective, caseseries 6/2
IV and oral dantrolene sodium vs oral
dantrolene sodium Not specified
Small uncontrolled
study
Medication side effects noted as
mild. Further studies on optimal
dose and efficacy compared to
other treatments necessary
Timms & Gibbons,
1986 [18]
Retrospective, case
series 11
9 pts received IV calcium gluconate with
diazepam or methocarbamol, 1 received
methocarbamol, meperidine
hydrochloride and nasogastric suction
and 1 received calcium gluconate and
methylprednisolone sodium succinate.
Two of the 11 patients also received L.
mactans antivenom 2.5 mg IV. 7/11 pts
required narcotic analgesics for pain.
Recovery Time
Small, uncontrolled
non-comparative
study
Latrodectism is responsive to
calcium gluconate with muscle
relaxant. AV is effective but
rarely necessary and may result
in serum sickness
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Ryan (1984) [17] reported on eight patients with severe muscular pain after bites by black
widow-spiders that were treated with the muscle relaxant dantrolene sodium. Six patients received
the medication both intravenously and orally while two patients received the oral preparation only.
Intravenous doses in this study varied between 0.5 mg/kg and 0.9 mg/kg and oral doses varied
between 25 mg and 100 mg given every four hours for 2–4 doses. Five of the six patients given both
intravenous and oral dantrolene sodium had good muscle relaxation. The two patients given only oral
doses had less satisfactory results. Overall it was noted that symptoms were more pronounced and
more protracted than had generally been reported with centrally acting muscle relaxant treatment.
Timms and Gibbons (1986) [18] reviewed the medical records of 11 patients admitted with
a diagnosis of latrodectism. Patients ranged from 14 to 60 years and recovery time was defined as the
interval between treatment and relief of symptoms. Positive identification of the spider L. mactans
was either made on a specimen by the ED physician or by an accurate description of the spider by
the patient. All patients had muscular pain; abdominal pain was experienced by 7/11 patients.
Nausea and vomiting occurred in four, headache in three and dyspnea in two. Most patients
were seen within two-hours. Nine of 11 patients received 10–20 mL of calcium gluconate in a 10%
solution intravenously in addition to muscle relaxants (diazepam or methocarbamol), one received
methocarbamol, meperidine hydrochloride and nasogastric suction and one received calcium gluconate
and methylprednisolone sodium succinate.
Two of the 11 patients also received L. mactans antivenom intravenously in addition to the calcium
gluconate and muscle relaxant. Of the 11 patients, seven required narcotic analgesics for relief of pain.
The authors concluded that latrodectism is generally self-limiting and responds to calcium and muscle
relaxant administration. While compromised patients can be treated with antivenom, it may result in
serum sickness.
Recommendations in a 1989 review by Binder [19] further advised the treatment of ‘common’
envenomation with 10% calcium gluconate intravenously titrated to relief of symptoms. Due to the
significant chance of hypersensitivity and serum sickness reactions with North American widow-spider
antivenom it was advised that this should be restricted to life-threatening cases only. The frequent
use of calcium therapy for latrodectism was questioned a few years later largely based on the case
series by Clark et al. (1992) [1], (Table 2). Their report was a notably a more comprehensive evaluation
compared with earlier studies. Firstly there was a much larger number of cases of black-widow
spider envenomation investigated, N = 163. Patients were categorized on severity depending on their
clinical presentation. This included symptom severity, physical findings and vital signs. A positive
identification of the spider was recorded in most (72%) cases. Measurable outcomes such as the average
time from envenomation until onset of symptoms (1.2 ± 1.6 h) and the average time from onset of
symptoms to hospital presentation (6.2 ± 7.8 h) were recorded. The most common complaint on
presentation was generalized muscular abdominal, back and leg pain and 36 patients were diaphoretic.
Forty-five patients were hypertensive with only six of these having a history of hypertension. Fourteen
patients presented with tachycardia. Twenty-two patients were sent home after evaluation in the
hospital Emergency Department (ED) but returned to an ED with recurring pain. Pain relief was
recorded as being most effective with either black widow spider-specific antivenom (L. mactans AV)
either alone or in combination with IV opioids (IV or IM morphine and/or meperidine) and muscle
relaxants (benzodiazepines). A total of 58 patients received antivenom with complete resolution of
symptoms in a mean time of 31 min from the end of the infusion, this was significantly shorter than
patients not treated with AV. Fifty patients reported pain relief after one vial and required no further
pain medication whereas seven patients required an additional vial. No patient needed more than
two vials of L. mactans AV. One patient died of severe bronchospasm after receiving antivenom and
had a history of asthma. Calcium gluconate was found to be ineffective with most moderate to severe
envenomation cases requiring the addition of IV opioids or other analgesics for symptomatic relief.
This finding was supported through later case reports, including one by O’Malley et al. in 1999 [20],
that detailed the treatment of latrodectism in a 13 year old male bitten by a black-widow spider while
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sleeping. The patient was initially treated in the ED of a nearby hospital with calcium gluconate and
analgesia with minor pain relief resulting. Although the patient was unable to walk he was discharged
only to present three days later at another ED where he was treated with one vial of L. mactans IV
antivenom 1 L of normal saline infused at a separate site. The authors report a successful response
to the antivenom 10 min later. It was concluded that administration of antivenom to patients with
prolonged or refractory symptoms of latrodectism may alleviate discomfort and weakness.
As a result of these reports calcium treatment of latrodectism declined and gave way to alternative
treatments that appeared to be much more effective for symptomatic relief. Opioid therapy in
combination with muscle relaxants for patients not eligible for antivenom treatment became the
recommended treatment for latrodectism [21,22] while antivenom was primarily reserved for severe
envenomation due to concerns of severe allergic reactions to whole IgG molecule Antivenom.
4. Antivenoms and Their Mechanism of Action
Antivenoms are antibody preparations that are produced from the plasma of animals, usually
horses or sheep, by injecting the animals with venoms. Due to their polyclonal nature antivenom
is able to neutralize multiple toxins within the venom [23]. Antivenoms can be either whole IgG
molecules, F(ab’)2 fragments or Fab fragments. Proposed mechanisms of how antivenom works in
humans includes blocking the active site of a toxin or binding to a toxin to prevent it interacting with
its substrate thereby neutralising the toxin. Central vascular compartment antivenom-venom complex
formation may prevent distribution of toxins to the target tissues such as the nervous system or cause
redistribution of the toxins from target tissues back to the vascular compartment. Antivenom may
also increase the rate of toxin elimination from the body depending on the relative clearance of the
antivenom and toxin [23,24].
A number of antivenoms produced against the venoms of specific Latrodectus spp. have
been developed in various regions around the world. These include the black-widow spider
(L. mactans) antivenom of North America (Merck), the red-back spider (RBS, L. hasselti antivenom)
in Australia (CSL, Ltd., Melbourne, Australia), the black-widow (L. indistinctus) and brown-widow
(L. geometricus) spiders of South Africa (SAFR), the Argentinian L. mactans, and the Mexican widow
spider (Aracmyn polyvalent antivenom for latrodectism and loxoscelism), and the discontinued
Yugoslavian widow-spider AV (L. tredecimguttatus) [25]. The ‘efficacy’ of antivenom is defined as its
ability to bind and neutralise venom-mediated effects under ideal conditions (in vitro studies and
animal studies of binding and neutralisation), while the ‘effectiveness’ of antivenom is defined as its
ability to reverse or prevent envenoming in human patients [26]. There is insufficient prospective
randomised controlled study evidence to lend support to the effectiveness of widow spider antivenoms.
However, a long history of relatively safe use and anecdotal or retrospective observational study
evidence means that antivenom continues to be used for severe cases of latrodectism. More recent
randomised controlled trials and a prospective case series of widow spider antivenoms support the
safety of the antivenom. These trials suggest that acute allergic-type reactions occur in about 5%
of cases, including anaphylaxis in 1–2% and delayed reactions or serum sickness in up to 10% of
cases [4,27–29]. The efficacy of widow-spider antivenom has been confirmed in the laboratory by
Graudins et al. [30] for red-back spider antivenom and for L. hesperus and L. mactans venoms in a mouse
envenomation model by Daly et al. [31].
4.1. Black Widow Spider Antivenoms
The first available black-widow spider antivenom was produced by Mulford Biological
Laboratories of Sharp and Dohme in the United States in 1936. This product was a lyophilized
normal horse serum. After a merger with Merck in 1953, an equine derived whole IgG Latrodectus
mactans antivenom was produced [14]. L mactans antivenom has been used to treat envenomations
from various widow spiders including L. hesperus, L. variolus, and L. bishop. The preferred route of
administration of Latrodectus spp. antivenoms varies from region to region. American black-widow
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antivenom is administered intravenously and has been associated with adverse effects more frequently
than antivenom made elsewhere. One report suggests that the anaphylaxis risk is 9% in those skin
testing negative and 80% in those skin testing positively, with a serum sickness rate of 36% [19]. A more
recent review [15] suggests that the black-widow antivenom has a similar safety profile to red-back
spider antivenom. In a 2012 review by Monte [14] it was revealed that the previously quoted incidence
of adverse reactions with the Merck black-widow spider antivenom were actually extrapolations from
studies on the whole IgG Wyeth Crotalidae antivenom. Further, it is expected that a purified F(ab)2
L. mactans antivenom called Analatro®, will have fewer adverse reactions when compared to the Merck
IgG product. A lack of allergic outcomes observed in a phase II clinical trial of Analatro® in 24 patients
by Stanford et al. [28] supports this. Despite this only 3.8% of patients with clinical effects attributed to
Latrodectism received antivenom from 2000 to 2008 [7] primarily due to the fear of adverse reactions to
the antivenom [1,15,25,32]. There have been two recent reports of anaphylaxis to L. mactans antivenom
(Antivenin®; Merck and Co., West Point, PA, USA) for black widow spider envenomation [33,34].
4.2. Red-Back Spider Antivenom
In Australia, red-back spider antivenom (RBSAV) has been available for use in the treatment of
latrodectism since 1956 [35]. RBSAV is an equine-derived antibody composed of purified IgG-F(ab)2
fragments produced by Commonwealth Serum Laboratories (CSL Ltd., Melbourne, VIC, Australia).
RBSAV neutralizes 1 µg of L. hasselti venom per unit of antivenom in vitro. It has been reported to reverse
envenomation by other widow spiders including the European widow spider L. tredecimguttatus [30]
however, aside from a much earlier report by Keegan [36] the efficacy of non-species-specific antivenom
for the treatment of widow spider envenomation was relatively unknown.
Graudins et al. (2001) assessed the in vitro and in vivo efficacy of RBSAV in the prevention of
toxicity resulting from other widow spider venoms [30]. In this study, the binding of RBSAV to five
Latrodectus spp. venoms and α-latrotoxin was assayed using Western blotting. Prevention of in vitro
and in vivo toxicity were tested in isolated chick biventer cervicis nerve-muscle preparation and male
mice, respectively. In Western blots, RBSAV bound to purified α-latrotoxin and similar molecular
weight widow spider proteins in all venoms tested indicating antigenic similarity with proteins found
in RBS venom. The antivenom also prevented typical in vitro muscle contracture and loss of twitch
tension seen with α-latrotoxin and the all venoms tested. Compared to control envenomed mice, mice
inoculated with venom pre-mixed with RBSAV remained free of envenomation signs. From this data it
was suggested that RBSAV may be clinically effective in the treatment of envenomation from other
widow spiders [30].
5. Clinical Studies of Antivenom Effectiveness
5.1. Non-Randomised Clinical Trials
Most of the case series (10 from 14), and case reports (9 from 14) discuss the effectiveness of
antivenom treatment for latrodectism. This includes three paediatric case reports and two paediatric
case series and one letter. The larger of these studies are summarized in Table 2.
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Table 2. Summary of non-randomised clinical studies for treatment of latrodectism with antivenom.
Study Author/s Type of Study N Treatment Efficacy Outcome Design Problems Study Conclusion/s
Sutherland &
Trinca, 1978 [37]
Retrospective case
series
2073/44
(IM/IV) RBSAV IM/IV Not specified
Reporting bias e. Data from
questionnaires included with AV
therefore no data on RBS bites that
did not require AV, missing data.
Multiple outcomes.
Difficult to elucidate—Signs and symptoms of
envenomation and general perception of ‘good’
outcome after antivenom but no quantitation of
outcome data presented.
Jelinek et al.,
1989, [38]
Retrospective case
series 150
RBSAV by IM if systemic
symptoms present, n = 32. Not specified
ED presentations only—May have
selected more serious cases.
11/32 pts given AV by IM needed more than
1 ampoule. Authors suggest this is because WA
red-back spider is more venomous.
Clark, 1992, [1] Retrospective caseseries 163
IV opioids and
benzodiazepines +58
patients received L mactans
AV by IV
Pain relief ≥30 min
after treatment
administered.
Retrospective review of case
notes—There was an attempt to
standardise with operational
definitions for data entry; strict
inclusion/exclusion criteria; small
group of toxicologists looking after
patients. Retrospective telephone
follow up for delayed AV reactions
could only be done in 9 patients.
Calcium gluconate was found to be ineffective
while L mactans AV significantly shortened the
duration of symptoms in severe envenomations.
Mead & Jelinek,
1993, [39]
Retrospective
Paediatric case series 241
21% of children
received RBSAV Not specified
Poorly defined criteria for systemic
envenomation—May result in
under-reporting.
Definite bite by RBS defined; syndrome in children
primarily similar to adults. Use of AV comparable
to previous studies in older age groups; however,
no child received more than one ampoule. Results
suggested that contrary to current opinion at the
time [40–43] children may not be at an increased
risk of morbidity from latrodectism.
Mollison et al.,
1994, [44]
Retrospective ICU
case series 32 26 patients received RBSAV
Partial, features of
red-back spider
envenomation in
Australian Aborigines
determined by
collecting data on
standard forms
Only severe cases (ICU)-reported, no
data kept on patients seen in ED.
Annual incidence of severe RBS bite calculated.
Unlike earlier series this study had a predominance
of female patients.
Dzelalirja &
Medic, 2003, [45]
Retrospective case
series & lab analysis 32
21 patients received
European WSAV
Pain intensity and
duration after
antivenom
Inadequate power for AV vs no
AV comparison
Latrodectism in Northern Dalmatia presents with
severe clinical symptoms. AV is advisable in the
treatment of all afflicted patients.
Trethewy et al.,
2003, [46]
Retrospective
Paediatric case series 54
45 patients received
IM RBSAV Not specified
Qualitative not quantitative
assessment of symptoms-patient
notes reviewed retrospectively.
Clinical signs/symptoms difficult to
define in children. For example, only
50% patients had a bite site
identified.
No statistically significant difference between age
groups for local or systemic envenomation even
though the older children were twice the weight of
younger group. This was in contrast to previous
studies suggesting envenomation is different in
children [37,47]. 46 children classified as systemic
envenomation and 38 of these received RBSAV.
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Table 2. Cont.
Study Author/s Type of Study N Treatment Efficacy Outcome Design Problems Study Conclusion/s
Isbister & Gray,
2003, [11]
Prospective case
series on calls to NSW,
QLD & WA Poison
Information Centres
and presentations to
two Hospital ED
(Sydney & Darwin).
68 with definite
RBS bite
6 patients received
IM RBSAV
Reported proportion
of 6 patients with no
pain at 24 h.
Study lacked power to compare IM
AV and no treatment.
The severity of envenomation should be defined by
the severity of pain and systemic features, AND
also to the duration of these effects. Only 1/6 of
patients receiving AV were pain-free at 24 h, an
unacceptable treatment effect. IM RBSAV was no
better than no treatment when all patients were
followed up over a week.
Nordt et al.,
2010, [48] ˆ
Retrospective case
series 96
All patients received
L. mactans AV Not specified
Published abstract only therefore
limited methodology explained.
Symptomatic treatment for black widow spider
envenomation includes opioid pain control and
muscle relaxants. Definitive treatment includes AV
to neutralize venom. Noted that adequate pain
control is often difficult to achieve. Although
derived from horse serum, hypersensitivity
reactions appear to be mild and rare but further
prospective studies are required to confirm.
Monte et al.,
2011, [7]
Retrospective case
series on Latrodectus
spp. exposures &
treatment reported to
US National Poison
Data System over 8
years.
9872
Patients received
benzodiazepines, calcium,
IV fluids or dilution/wash
of bite site. 374 (3.8%)
patients received
L. mactans AV.
Not specified
Only cases reported to US poison
centers reviewed. Dataset contained
no information on dosing or timing
of treatments. Unable to differentiate
adverse drug reactions for the
different treatments as most patients
received multiple therapies and the
dataset does not attribute ADRs to
the specific treatment given.
Few patients received AV although it was
associated with shorter symptom duration (<24 h)
in moderate and major severity groups. There was
no evidence of shorter symptom duration in
patients who received benzodiazepines or calcium.
Adverse drug reactions were more common in
patients receiving benzos and AV.
Basanou et al.,
2015, [49] ˆ
Retrospective case
series of Poisons
Centre consults
53
Mod to severe cases (23/53)
treated with IV benzos,
n = 6, IV opioids n = 5 or
combination of both n = 12.
IV L. mactans AV in 5
patients with severe
systemic effects.
Not specified possibly
“symptomatic
control”
Published abstract only therefore
limited methodology explained.
Opioid analgesics combined with muscle relaxants,
such as benzodiazepines, are generally effective at
symptomatic control. In selected severe cases
antivenom is the most efficacious therapy available.
ˆ Conference publication only available. RBSAV: Red-back spider antivenom.
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The largest case series of antivenom treatment for latrodectism was in Australia by Sutherland
and Trinca (1978). They reported on 2144 case reports made to the red-back spider antivenom (RBSAV)
manufacturer Commonwealth Serum Laboratories (CSL)™. Over eight years, an average of 240 cases
per annum were reported. Local pain, redness and swelling were the most common symptoms.
General effects included nausea, vomiting and sweating. Coma and respiratory failure were very
uncommon. The investigators attributed this to the use of specific antivenom within 24 h of the bite in
92% of cases and within 2 h in 70% of cases. Only forty-four patients received antivenom intravenously.
In the majority of cases, (2073) the intramuscular route was used [37]. There were 11 cases (0.5%) with
anaphylactic reactions reported, with no deaths from venom or antivenom reactions. A similar number
of delayed antivenom reactions were reported. This study was based on cases treated with antivenom
and then reported to the antivenom manufacturer. As a result, patients with greater initial severity
and a favorable treatment response may have been reported. Jelinek et al. (1989) [38] conducted a
retrospective study of one hundred and fifty patients admitted to hospital with a definite red-back
spider bite in Western Australia. Thirty-two (21%) patients received antivenom with 11 (34%) receiving
more than one ampoule. This was in contrast to the Sutherland and Trinca series where only 3% of
patients received more than one ampoule. The authors stated that this result suggested that the Western
Australian red-back spider was more venomous compared to other Australian red-back spiders as more
antivenom was needed for a clinical response. The alternative interpretation, that the effectiveness of
the antivenom was less than originally believed, was not considered. Indeed it is difficult to understand
how RBSAV effectiveness was reported in these two studies as, criteria and time course for ‘treatment
success’ were only vaguely specified. RBSAV effectiveness in the Jelinek et al. study was defined as
patients becoming ‘asymptomatic’ ‘sometime’ after antivenom administration [39]. In the Sutherland
and Trinca study favourable comments such as ‘good’, ‘improved’, ‘successful’ ‘cured symptoms’
written on the AV pack questionnaire were considered evidence of a treatment success. It is interesting
to note that 1185 cases were deemed successful in the Sutherland and Trinca report, but there was no
improvement reported in 68 cases and no comment on efficacy reported in a further 809 cases from a
total of 2062 patients that definitely received (pack questionnaire completed) RBSAV [37].
In the United States, Nordt et al. (2010) [48] performed a retrospective review of a poison
centre electronic database from January 1999 to December 2009. All cases of black-widow spider
envenomation treated with L. mactans antivenom (Merck) were included. Age, gender, signs and
symptoms, adjunctive therapy, number of vials of AV given, response to AV, and adverse reaction
to AV were recorded. The aim of this study was to determine rate of adverse effects and the efficacy
of AV in patients treated for latrodectism, as AV use had been previously limited due to concerns of
possible severe allergic reaction. Ninety-six adult and paediatric patients were treated with L. mactans
AV. No patient required more than one vial of AV. One patient developed urticaria to the antivenom
halfway through the infusion and this was immediately discontinued. Another patient developed
generalized erythema following completion of infusion but no other effects. There were no deaths in
any patients receiving AV. All patients reported pain relief with AV and did not require additional
AV doses. Adjunctive therapies included opioids 69%, benzodiazepines 64%, calcium 21%, NSAIDs
17%, and other muscle relaxants 11%. No cases of serum sickness were reported. From this study the
investigators concluded that treatment for black widow spider envenomation includes opioid pain
control and muscle relaxants and while these medications can provide symptomatic relief they do
not neutralize the venom. It was advised that definitive treatment include antivenom although they
noted that adequate pain control was often difficult to achieve. Hypersensitivity reactions appeared to
be mild and uncommon, however the authors recommended that further prospective studies were
required to confirm these results.
In a more recent retrospective review Basanou et al. (2015) [49] investigated L. mactans exposures
reported to the National Poison Centre of Greece. Fifty-three patients ranging from 2–74 years were
reviewed. Symptoms typically lasted for 1–3 days and included abdominal pain (52%), muscle
rigidity/cramping (43%), diaphoresis (43%), and other symptoms attributable to the envenomation.
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Moderate to severe symptoms were treated with IV benzodiazepines (n = 6), IV opioids (n = 5) or
combination of IV opioids with benzodiazepines (n = 12). L mactans antivenom was administered in
five patients with severe systemic symptoms. Treatment relieved pain in 48% of patients taking opioids
or benzodiazepines alone, and in 52% using opioids with benzodiazepines. All five patients receiving
AV reported complete symptom resolution after 80 ± 30 min. The investigators concluded that opioid
analgesics combined with muscle relaxants (benzodiazepines), are generally effective at symptomatic
control and in selected severe cases antivenom was the most efficacious treatment available.
Mead & Jelinek (1993) [39] aimed to describe the pattern of illness caused by red-back spider bites
to children in Perth, Western Australia over a 10 year period and to compare it with that in adults.
The case-notes of 241 children with suspected RBS bite were reviewed. A strength of this study was the
defining of a ‘definite RBS bite’ according to the following: (1) definite bite by a positively identified
red-back spider; or (2) positive identification of a red-back spider with no definite bite but the later
development of typical symptoms; or (3) no definite history of red-back spider bite but strong clinical
evidence and complete recovery after administration of antivenom. Sixty-five percent of children
were definitely bitten. The syndrome produced in children was usually similar to that seen in adults.
Twenty-one percent of children received antivenom, a rate comparable to previous studies in older
age groups [38]; however, no child received more than one ampoule and it was deemed that no child
remained unwell after a single dose of antivenom. These findings suggest that, contrary to current
opinion at the time [40–43], children may not be at an increased risk of morbidity from latrodectism.
The limitations of this study largely reflect the problems of retrospective case reviews, with a lack
of uniform recording of signs/symptoms and response. Importantly there was no quantification of
antivenom effectiveness. Of those children not treated with antivenom (209/241), most (67%) were
observed and given no treatment.
Trethewy et al. (2003) [46] reviewed the case notes of children under 12 years of age with
a discharge diagnosis of red-back spider bite over a 81/2 year period from a central Australian hospital.
There were 54 patients, 39 Aboriginal and 15 non-Aboriginal. Cases enrolled in the study were stratified
on the basis of history of bite. A definite bite was recorded if the carer positively identified an RBS and
observed it bite the child, or a positive identification of the spider with no definite bite, but the later
development of typical symptoms of latrodectism, necessitating review. No definite history of RBS bite
was recorded if there was no historical evidence of bite, but strong clinical evidence for envenomation,
with complete resolution of symptoms after administration of specific antivenom. Results were
stratified to allow comparison of envenomation profiles for different ages and average body mass.
Symptoms and signs were also stratified into local and systemic features of envenomation consistent
with previous studies [37,39]. Forty-six children (85%) had systemic envenomation. The three most
common systemic features were irritability, hypertension and sweating and 35 children (65%) had all
three symptoms. There was no significant difference in the clinical characteristics and outcomes of
envenomation between the Aboriginal and non-Aboriginal children. Forty-five (83%) children received
antivenom therapy (RBSAV), 39 (72%) received one ampoule, and six (11%) required two ampoules.
To protect against AV acute adverse reactions, twenty-five (56%) children received an antihistamine
premedication 15–30 min before administration of antivenom while sixteen children (36%) received a
combination of antihistamine, and adrenaline. Four children (9%) received no premedication. In all
cases the antivenom was reported to be efficacious, with complete resolution of the signs and symptoms
of envenomation. There were no reports of hypersensitivity reaction in any child treated. This study
provided a comprehensive description of the clinical features and outcomes of RBS envenomation in
children but did not quantify the time course of the outcome nor have a comparator treatment group.
According to the product information, RBSAV is to be administered undiluted intramuscularly.
More severe cases of envenoming are commonly treated with diluted antivenom intravenously.
However, some cases have received undiluted antivenom intravenously. While RBSAV has a very low
acute reaction rate, half of the allergic reactions reported by Sutherland and Trinca (1980) following its
use were attributed to administration of undiluted antivenom by the intravenous route [30,37]. Case
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studies have reported multiple ampoule use of RBSAV to treat severe envenomation without significant
adverse reactions [37,38,50]. Isbister (2007) [29] reviewed the safety of appropriately given dilute IV
RBSAV in a larger study of ninety-five patients including 13 children. All patients had local pain,
68 had radiating pain, 54 had diaphoresis and 37 had systemic effects from the latrodectism. Prior to the
IV antivenom, forty-two patients had received at least one vial of RBSAV intramuscularly. The median
dose of IV RBSAV was two vials. Four of the patients had immediate systemic hypersensitivity
reactions after commencement of the IV RBSAV. No patient had a severe reaction, one had a moderate
reaction and three had mild reaction. Three of 32 patients followed-up 1–2 weeks later developed
symptoms of serum sickness [29]. Antivenom concentrations on serial blood samples using an
enzyme immunoassay following IV and IM administration of RBSAV in envenomed patients was
also tested by Isbister et al. (2008) [51]. In the serum samples of 10 patients who had received IM
RBSAV, immunoassay did not detect antivenom at any time point after one or more vials had been
administered. In ten patients who received one or more vials of IV RBSAV the antivenom was detected
in all patient serum samples. Consistent with earlier human and animal studies of intramuscularly
administered antivenom, it appeared that IM RBSAV did not reach the systemic circulation and as a
result may not be effective [51].
5.2. Randomised Clinical Trials of Antivenom for Latrodectism
We identified three placebo-controlled randomised trials [52–54] and two no-placebo randomised
comparator trials [4,27] of antivenom for Latrodectism (Table 3).
In the first full-publication no-placebo randomised comparator trial, Ellis et al. (2005) [27]
randomised eligible patients across five participating sites to RBSAV by IM injection (n = 15) or RBSAV
by IV infusion (n = 18). The aim of this study was to determine which route of AV administration was
more effective for treating latrodectism. This study was very under-powered, two patients dropped out
and more pre-antivenom analgesia was used in the IV group (8/17, 47%) resulting in lower baseline
pain scores than for the IM group where (3/14, 21%) had pre-AV analgesia. The primary 1-h pain
measure outcome was actually a 30-min pain measure for the IV group given the time taken to run the
infusion. Six from 14 patients in the IM group and one from 17 patients in the IV group did not have
pain scores recorded at 2 h also limiting the value of comparison at this point. Previous studies claimed
that the majority of patients with RBS bite (between 66% and 97%) were adequately treated with one
ampoule of antivenom. Using a protocol that repeated treatment in non-responders, this trial found
only a small proportion of patients (21%) responded to only one ampoule. Twelve from 39 patients
who remained in the trial after randomisation required IV rescue therapy making the endpoint number
of ampoules administered much less useful. The mean number of antivenom ampoules used by the
two groups was similar (IM = 2.5 ampoules; IV = 2.6 ampoules), the maximum number of ampoules
used was seven. Irrespective of the methodological problems mean pain scores on a 100 mm visual
analogue scale were seen to fall over the first hour after treatment for both groups (IM VAS: 67 mm
pre-AV to 34 mm post-AV) versus (IV VAS: 54 mm pre-AV to 41 mm post-AV) with no significant
difference between the two groups found. At 24 h significantly more patients in the IV group (13/17;
76%) were pain free than in the IM group (3/14; 21%), Figure 1. Length of stay was less than one day
for all patients although three IM patients re-presented to hospital over subsequent days for more
antivenom. Minor adverse effects were relatively common, including itch, nausea and shivering and
one patient in the IV group had flu-like back pain for 10 days (serum-sickness reaction). No adverse
event required treatment. The investigators were unable to conclude which route of administration for
antivenom was better. The authors suggested that both routes were equally effective at relieving initial
pain. However, this may also be interpreted that both routes were equally ineffective, given the overall
need for repeated treatments.
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Table 3. Summary of randomised controlled clinical trials of antivenom treatment for latrodectism.
Study
Author/s
Number in
Each Arm Blinded
Allocation
Concealed AV Dose/Brand Primary Outcome/s Conclusion/s
Ellis et al.,
2005 [27]
15/18 (IM
AV/IV AV) Yes
Yes (1 from each arm
was unblinded and
removed from the
analysis)
500 units RBS Antivenom
(CSL Ltd., Melbourne, Australia)
Partially defined 2:
number of AV
ampoules used and
pain scores up to 2 h.
Both IM and IV RBSAV were deemed effective as after
1 h-pain VAS fell, with a better outcome at 24 h for the IV
route. There were some major and acknowledged study
limitations including too small sample size, and an
insensitive primary outcome (N of AV ampoules) Thus the
study was underpowered and inconclusively negative.
Isbister et al.,
2008 [4]
62/64 (IM
AV/IV AV) Yes Yes
1 or 2 vials of RBS Antivenom
(equine Fab’2 500 U/vial,
CSL Ltd., Australia)
Pain at 2 h after
treatment
administered.
No real difference in IV and IM routes. Further, RBSAV
may provide no benefit over placebo.
Dart et al.,
2013 [53]
13/11
(AV/placebo) Yes Yes
3 vials of Antivenom Latrodectus
(Black Widow) Equine Immune
F(ab)2 (Analatro®, Instituto
Bioclon S.A. de C.V., Mexico).
VAS pain intensity at
150 min after
treatment
administered.
No difference between BWAV and placebo pain VAS *
Isbister et al.,
2014 [54]
112/112
(AV/placebo) Yes Yes
2 vials of RBS Antivenom
(equine Fab’2 500 U/vial,
CSL Ltd., Australia)
Yes, pain at 2 h after
treatment
administered.
No difference between RBSAV and placebo pain VNRS **
Dart et al.,
2016 [52] ˆ AV/placebo Yes ˆ Yes ˆ
1 to 2 doses of F(ab’)2
Antivenom (Analatro®)
Treatment
failure-pain at 48 h
after treatment
administered.
F(ab’)2 AV was effective at reducing moderate to severe
pain caused by latrodectism, however a 1-sided hypothesis
test was used. No serious safety concerns were identified ˆ
* VAS: Visual Analogue Scale; ** VNRS: Verbal Numerical Rating Scale. ˆ Published conference abstract only therefore limited information on methodology and outcomes available
for review.
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The ‘RAVE’ study by Isbister et al. (2008) [4] also compared IM and IV antivenom administration
for RBS bite in a considera ly larger clinical tri l than that of Ellis. This multicentre, randomised
double-dummy, double-blind study had a primary outc me of clinically sig ificant reduction in pain
2 h after treatment. All patients rece ved the same pre-a tivenom analgesic regimen, the met od of
administration was randomised and repeated clinic l ass ss ents were perfor ed at 30 min intervals
fter completion of t eatment. Sixty-two patients received IM antivenom and 64 r ceived IV antivenom.
After antiv n m treatment, pa n improved i 40/64 (62%) in the IV group versus 33/62 (53%) i the
IM group, (Figure 1). In 55 tients with systemic effects, pain impr ved in 58% after IV antivenom
versus 65% after M antive om. Twenty-four hours after antivenom, pain had impro d in 84% of
the IV g oup and 71% of the IM group. A m ta-analysis, including data from the Ellis et al. study,
found no diff rence in the primary outcome between IV antivenom (probabilit of success 55%) and
IM antivenom (probability of success 51%) [4].
Dart et al. (2013) [53] conducted a multi-centre randomised, placebo-controlled clinical trial in
patients at least 10 years old with moderate to severe latrodectism foll wi g b ack-widow spider
bite. Subjects had to present for treatment within 72-h of symptom onset with a clinical diagnosis of
latrodectism made by an investigator and a independent physician. Subjects also needed t have
a visual analogue scale (VAS) pain score of t least 40 mm on presentation screening and immediat ly
before i fusion of the study drugs. From 24 ubjects, 13 were rand mised to a single 10-min IV
in usion of three vials of antivenom and 11 to placebo IV infusion. This was a phase-2 c inical trial of
a F(ab)2 an iv nom (Anala ro) not yet available for clinical se. Pain was assessed using a 100 mm
VAS. The pr mary outcome was a median ch ng in VAS at 150 min post-tre tment. This was −50
in the antivenom group and −46 m n the placebo group (no statistically significant difference).
A secondary outc e was time to a clinically important decrease in pain defined as decreas of at
least 13 mm in posttr atment VAS p in score co pared with baseline VAS pain score. The median time
to a clinically importan d crease in pain aft r treatm nt as significantly shorter in the antiv nom
group (30 mi [IQR 30, 60 mi ]) comp r d with the placebo group (90 min [IQR 30, 90 min]) (p = 0.03).
A second meas re of analgesic efficacy was a comparison of roportion of patients who did not
reach a threshold of pain r lief by end of the study period (‘treatment failures’). In this study the
Toxins 2017, 9, 148 14 of 20
proportion of treatment failures in the placebo group was 64% compared with 23% in the antivenom
group, (Figure 1). No serious adverse events or deaths were reported for either intervention and
there were no significant differences in occurrence or relatedness of adverse events within the two
treatment groups. Design limitations of this study included a small sample size, the average time
difference between presentation and treatment for the patient groups—patients in the antivenom
group presented on average 4-h later than the placebo group. The investigators acknowledge that
this may have reflected a difference in disease severity or could have altered the treatment efficacy
or natural progression of disease during the study period. A further study limitation was protocol
non-compliance. There were 23 protocol deviations reported in 11 subjects (five in the AV group and six
in the placebo group). These deviations included incorrect administration doses of allowable analgesics
and consequently, inconsistencies with the recording of the pain score. The investigators suggest
that these violations, whilst prevalent in both groups, may have biased the study toward finding no
difference between the study groups. Finally the difficulty in diagnosing latrodectism was mentioned
as a limitation of this study. This study was partly funded (and one of the authors employed) by the
manufacturers of Analatro F(ab)2 antivenom [Instituto Bioclon S.A. de C.V., Talapalan, Mexico].
The most recent full-publication multi-centre randomised placebo-controlled clinical study was
performed by Isbister et al. (2014) [54]. This study investigated the effectiveness of red-back
spider antivenom for latrodectism in 224 patients over 7-years of age. Inclusion criteria were
specified: a red-back spider bite where the treating clinician would normally administer antivenom
or analgesia for the pain, or for systemic envenoming. Red-back spider bite was pre-defined as
either a bite by a spider that was clearly identified as a red-back spider (by the patient or clinician)
or a clinical syndrome consistent with typical red-back spider envenoming, that is, the sensation
of a bite followed by two or more of: increasing pain during the first hour, radiating, regional, or
generalised pain, and local or regional diaphoresis. Local envenoming was pre-defined as severe local
pain, for which the patient was requesting analgesia, or that was preventing sleep while systemic
envenoming was defined as the presence of three or more of the following: nausea, vomiting,
headache, lethargy, malaise, and abdominal pain. Exclusion criteria were; patients younger than
8-years (because of the unreliability of the Verbal Numerical Rating Scale for assessment of pain in
this group), prior administration of antivenom and presentation to hospital more than 36-h after the
bite. All eligible patients were randomised to blinded treatment with RBSAV or placebo, according
to a computer-generated randomisation code. Prior to the study intervention all patients received
standardised analgesia. Each treatment kit contained 2-blinded vials of either RBSAV or normal saline
solution (placebo). The content of each treatment pack was unknown to the treating clinician, patient
and study investigators. The trial drug was administered (two vials of RBSAV or two vials of placebo)
mixed in 200 mL of normal saline given over 20-min. The primary outcome was a clinically significant
reduction in pain two hours after commencement of the study treatment. The Verbal Numerical
Rating Scale (VNRS) was used as in the RAVE I study. A second primary outcome was number of
subjects with a resolution of systemic features of envenoming within two hours in the subgroup with
systemic envenoming.
Secondary outcomes were predefined as clinically significant reduction in pain and resolution
of systemic features (if present) at four hours, administration of opioid analgesics (oral or parenteral)
or further doses of antivenom after two hours, a clinically significant reduction in pain at 24 h, use
of opioid analgesia after discharge, representation for medical care, acute systemic hypersensitivity
reactions, and serum sickness defined as three or more characteristic symptoms (fever, malaise, rash,
itchiness, myalgia, and arthralgia). Predefined subgroup analyses were planned for patients with
systemic envenoming. A number of processes were put in place to ensure continued blinding of
investigators to treatment groups until the final analysis was approved. Of the 224 patients, 112 were
randomised to receive RBSAV and 112 were randomised to receive placebo. Twenty-six of 112 patients
(23%) from the placebo arm had a clinically significant improvement in pain (treatment success)
compared to 38 of 112 (34%) from the antivenom arm, Figure 1 (difference in favour of antivenom
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10.7%; 95%CI:−1.1% to +22.6%; p = 0.10, not statistically significant). Systemic effects resolved after 2 h
in nine of 41 patients (22%) in the placebo arm and nine of 35 (26%) in the antivenom arm. This was also
not statistically significantly different. There was no significant difference in any secondary outcome
between antivenom and placebo, including pain at four and 24 h, systemic features at four hours, and
the use of rescue opioid analgesia and antivenom.
The authors acknowledged that the sample size may have been too small to completely exclude
a small benefit from antivenom, however, the calculated number needed to treat (NNT) for benefit
from antivenom was 10 patients. That is, for every 10 patients that receive antivenom only one patient
will obtain significant pain relief. This is a very poor result for an analgesic treatment. Meta-analyses
of effective analgesic treatments generally report a NNT of 2 to 4. Another limitation was that some
cases were included according to a clinical diagnosis of latrodectism rather than a witnessed bite.
This is a limitation of most latrodectism studies that might bias towards observing no treatment effect.
Notably, a reanalysis of the primary outcomes including only cases in which the spider was identified
resulted in the same outcomes. Finally, the authors noted that the measured pain outcomes had not
been previously validated in this condition, which could result in either an under or over-estimation
of the measured treatment effects. However, this would have affected both arms of the study, a similar
primary outcome was used in two previous studies with one resulting in a negative outcome and the
other resulting in a positive result [4,55]. The VNRS and VAS measures of pain have been found to be
strongly correlated in both clinical research and in the Emergency Department for acute pain [56–58].
The VNRS has the added advantage of being easier to administer by the clinician and easier to
understand by the patient.
The most recent multicentre, placebo-controlled randomised clinical trial of antivenom for
latrodectism is by Dart et al. (2016) [52]. The authors published a conference abstract investigating
the effectiveness and safety of the Analatro® F(ab’)2 black widow antivenom. Sixty patients were
randomised to one of two treatment groups, F(ab’)2 AV or saline placebo. Patients with moderate
to severe pain measured using the VAS were enrolled and treated. Pain intensity was measured at
baseline and every 30 min thereafter up to 150 min. Patients with moderate to severe pain or those
who failed to achieve a clinically significant reduction in pain after the first dose received a second
dose. The primary outcome measure was treatment failure, defined as failure to achieve and maintain
a clinically significant reduction in pain for 48 h post-treatment. This primary outcome measure was
reported to be “statistically significant” when analysed using a 1-sided Chi-squared test (Treatment
Failures: 15/29 AV vs. 24/31 placebo). When the data is re-analysed using an appropriate 2-sided or
2-tailed Fisher’s exact test a non-significant p-value of 0.0576 is computed. The treatment failure rate
is also just over 50% in the AV group. Treatment Success: 14/29 AV vs. 7/31 placebo is presented in
Figure 1. As this RCT is a published abstract there is currently insufficient detail on the methods and
other outcomes such as pain intensity for the two treatments over time and the frequency and types of
adverse effects.
5.3. Meta-Analysis of Randomised Controlled Trials of Antivenom for Latrodectism
The forest plot (Figure 2) shows a small overall benefit of IV antivenom over IM antivenom or
placebo on pain response. However, on closer inspection it is the smaller underpowered studies that
tend to favour IV antivenom rather than the larger studies. If the risk difference for each study is
converted to the number needed to treat in order to have a successful treatment outcome with IV
antivenom, the smallest studies of Ellis et al. (2005), which had a sample size (SS) of 31, and Dart et al.
(2013), which had a sample size of 24 have the lowest NNT of 2. When the sample size is larger the
NNT is seen to increase to 4 for Dart et al. (2016), SS of 60 and to NNT = 9 and, 11 for Isbister et al.
(2014) and (2008) (SS = 224 and SS = 126), respectively. The smaller studies show extreme differences
that are not replicated in the larger studies. This is likely due to significant heterogeneity, as indicated
in the RevMan analysis of heterogeneity suggesting non-random effects in the differences seen; bias
such as selective reporting or statistical analysis. That the two trials with the largest effect sizes are
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industry sponsored raises concerns about whether this influenced the conduct or analysis of the
trial. For example, the original sample size for Dart 2016 was 50, but was subsequently revised to
60. The trial is on the cusp of statistical significance, (falling each side, depending on choice of test),
and it is unclear if there were interim or serial analyses with post hoc adjustment of sample size to
achieve even this result. Irrespective of these potential biases, the pooled analyses which include these
small studies results in a NNT of 5. If regarded as simply an analgesic therapy, this is a very expensive
intervention of an uncertain benefit for four out of five patients. Further the adverse effect profile
would be considered poor compared to most other analgesic alternatives.
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6. Discussion
Latrodectism or envenomation by widow spiders is common worldwide and is the most common
clinically significant spider envenomation. The venom contains alpha-latrotoxin, a neurotoxin that
can result in an incapacitating syndrome of severe local, regional or systemic pain and autonomic
features that, if left untreated, can last from several hours to days. Severe and persistent pain occurs in
a half to two-thirds of Latrodectus cases and is the primary target of effective treatments. The literature
on the clinical effectiveness of past and current treatments for latrodectism shows several phases as
various treatments have swung in and out of favour. Earlier latrodectism drug treatments included
calcium gluconate, muscle relaxants and opioid analgesia either combined or in isolation. These earlier
treatments were based on anecdotal case reports and small case series with varying reports on patient
effectiveness. A larger case series by Clark et al. in 1992 cast considerable doubt on the effectiveness of
first-line calcium tr atm nt for latrodectism. Calcium gluconate was then judged to be ineffective in
symptom relief and opioid th rapy in combination with muscle relaxants becam the rec mmended
treatment for latrodectism. Antiv nom was prim rily reserved for severe enve omation cases due
to the perceived significant chance of hypersensitivity and serum ickness reactions. Furth r more
rigorous studies suggest these risks were overstated, but also c ll into question whether antivenom
has enough cli ical benefits to warrant use at all.
An equine-derived IgG-F(ab)2 red-back spider antivenom (RBSAV) has been available for use in
Australia for the last sixty years. It has a very low acute reaction rate and half of the allergic reactions
following its use have been attributed to administration of undiluted antivenom by the intravenous
route. The American equine derived whole IgG black widow spider L. mactans antivenom has also
been available for the last sixty or so years. It is administered intravenously and has been regarded
as having more frequent adverse effects than Australian RBSAV. The 2001 review by Clark suggests
that the black widow spider antivenom has a similar safety profile to the red-back spider antivenom.
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Despite this only 3.8% of patients with clinical effects attributed to Latrodectism received black widow
spider antivenom from 2000 to 2008 primarily due to the fear of adverse reactions to the antivenom.
The effectiveness of antivenom for red-back spider envenoming was considered excellent for
many years based on case series collated by the manufacturer [37].The limitations and biases of these
early reports of effectiveness are obvious in hindsight, but were only drawn to notice when better
designed prospective studies noted low treatment effectiveness. This was followed by randomised
comparator trials Ellis et al. (2005) and Isbister et al. (2008) which found no significant difference
between intramuscular and intravenous RBSAV treatment on pain relief. Subsequent, multicentre
placebo-controlled randomised trials also show poor treatment responses and no statistically significant
differences. In all these studies there has been a non-significant trend towards a minor positive effect.
However, the clinical responses in these prospective studies have consistently been much less than
the older uncontrolled studies reported. Further, the differences between AV and control groups have
generally been much less than the decline due to other treatments and the natural history of resolution.
In conclusion, this review suggests that current and past treatments are generally ineffective in
providing rapid adequate symptom relief for patients with Latrodectus spp. envenoming. Ongoing
investigation into the mechanism of latrodectism is essential as this may lead to more effective
treatments being developed. Investigation into alternate pain treatments utilising placebo-controlled
randomised clinical trials are urgently needed.
7. Materials and Methods
We searched MEDLINE, EMBASE and Google Scholar from 1946 to December 2016 and included
any clinical studies of latrodectus envenoming with treatment, including antivenom and other medical
treatments such as analgesia and calcium. The following keywords were used: “red-back spider”,
“widow spider”, “latrodectism”, “antivenom” and “treatment”. Reference lists of identified articles
were searched to find additional publications. Only articles less than 40 years old and in English were
reviewed. We identified a total of 48 studies of which 34 were included for review. There were two
full-publication and one abstract placebo-controlled randomised trials, two randomised (no placebo)
comparative trials, 14 case series (including two abstracts), 14 case reports, and one letter discussing
the effectiveness of treatments for latrodectism. Four of the case reports and two of the case series
were on paediatric patients. We performed a meta-analysis on the five randomised controlled trials
that investigated the effectiveness of antivenom on pain from latrodectism using RevMan 5 software
[Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane
Collaboration, 2014]. We compared the Ellis et al. (2005) and Isbister et al. (2008) RCT’s of IV
Antivenom versus IM Antivenom (both using RBSAV, CSL Ltd. Melbourne, Australia). We then
compared the Dart et al. (2013), Dart et al. (2016) (Latrodectus (Black Widow) F(ab)2 (Analatro, Instituto
Bioclon S.A. de C.V., Mexico City, Mexico) and Isbister et al. (2014) (RBSAV, CSL Ltd., Melbourne,
Australia) RCT’s of IV Antivenom versus saline placebo. We calculated the risk differences and 95%
CI using the Mantel-Haenszel method, and a random effects model due to the different outcome
definitions for the pooled estimate. We presented the outcomes in a Forest Plot again using RevMan
V5.3 and calculated the Numbers Needed to Treat (NNT) for each study.
Acknowledgments: Nicole M. Ryan is supported by an NHMRC Early Career Fellowship Award ID 1072056.
Conflicts of Interest: The authors declare no conflict of interest. The funding sponsors had no role in the writing
of this manuscript.
References
1. Clark, R.F.; Wethern-Kestner, S.; Vance, M.V.; Gerkin, R. Clinical presentation and treatment of black widow
spider envenomation: A review of 163 cases. Ann. Emerg. Med. 1992, 21, 782–787. [CrossRef]
2. Saucier, J.R. Arachnid envenomation. Emerg. Med. Clin. N. Am. 2004, 22, 405–422. [CrossRef] [PubMed]
Toxins 2017, 9, 148 18 of 20
3. Thorp, R.W.; Woodson, W.D. The Black Widow Spider: (Formerly: Black Widow; America’s Most Poisonous Spider);
University of North Carolina Press: Raleigh, NC, USA, 1945.
4. Isbister, G.K.; Brown, S.G.; Miller, M.; Tankel, A.; Macdonald, E.; Stokes, B.; Ellis, R.; Nagree, Y.;
Wilkes, G.J.; James, R.; et al. A randomised controlled trial of intramuscular vs. intravenous antivenom for
latrodectism—The RAVE study. QJM 2008, 101, 557–565. [PubMed]
5. Isbister, G.K.; Fan, H.W. Spider bite. Lancet 2011, 378, 2039–2047. [CrossRef]
6. Nicholson, G.M.; Graudins, A. Spiders of medical importance in the Asia-Pacific: Atracotoxin, latrotoxin
and related spider neurotoxins. Clin. Exp. Pharmacol. Physiol. 2002, 29, 785–794. [CrossRef] [PubMed]
7. Monte, A.A.; Bucher-Bartelson, B.; Heard, K.J. A US Perspective of Symptomatic Latrodectus spp.
Envenomation and Treatment: A national poison data system review. Ann. Pharmacother. 2011, 45, 1491–1498.
[PubMed]
8. Hlubek, M.D.; Stuenkel, E.L.; Krasnoperov, V.G.; Petrenko, A.G.; Holz, R.W. Calcium-Independent Receptor
for a-Latrotoxin and Neurexin 1a Facilitate Toxin-Induced Channel Formation: Evidence That Channel
Formation Results from Tethering of Toxin to Membrane. Mol. Pharmacol. 2000, 57, 519–528. [PubMed]
9. Lelianova, V.G.; Davletov, B.A.; Sterling, A.; Rahman, M.A.; Grishin, E.V.; Totty, N.F.; Ushkaryov, Y.A.
α-Latrotoxin Receptor, Latrophilin, Is a Novel Member of the Secretin Family of G Protein-coupled Receptors.
J. Biol. Chem. 1997, 272, 21504–21508. [CrossRef] [PubMed]
10. Khvotchev, M.; Südhof, T.C. α-latrotoxin triggers transmitter release via direct insertion into the presynaptic
plasma membrane. EMBO J. 2000, 19, 3250–3262. [CrossRef] [PubMed]
11. Isbister, G.K.; Gray, M.R. Latrodectism: A prospective cohort study of bites by formally identified redback
spiders. Med. J. Aust. 2003, 179, 88–91. [PubMed]
12. Maretic´, Z. Latrodectism: Variations in clinical manifestations provoked by Latrodectus species of spiders.
Toxicon 1983, 21, 457–466. [CrossRef]
13. Ballantyne, J.C.; Carr, D.B.; deFerranti, S.; Suarez, T.; Lau, J.; Chalmers, T.C.; Angelillo, I.F.; Mosteller, F.
The Comparative Effects of Postoperative Analgesic Therapies on Pulmonary Outcome: Cumulative
Meta-Analyses of Randomized, Controlled Trials. Anesth. Analg. 1998, 86, 598–612. [CrossRef] [PubMed]
14. Monte, A.A. Black widow spider (Latrodectus mactans) antivenom in clinical practice. Cur. Pharm. Biotechnol.
2012, 13, 1935–1939. [CrossRef]
15. Clark, R.F. The Safety and Efficacy of Antivenin Latrodectus mactans. J. Toxicol. Clin. Toxicol. 2001, 39,
125–127. [CrossRef] [PubMed]
16. Key, G.F. A comparison of calcium gluconate and methocarbamol (Robaxin) in the treatment of latrodectism
(black widow spider envenomation). Am. J. Trop. Med. Hyg. 1981, 30, 273–277. [PubMed]
17. Ryan, P.J. Preliminary report: Experience with the use of dantrolene sodium in the treatment of bites by the
black widow spider Latrodectus hesperus. J. Toxicol. Clin. Toxicol. 1984, 21, 487–489. [CrossRef]
18. Timms, P.K.; Gibbons, R.B. Latrodectism—Effects of the black widow spider bite. West. J. Med. 1986, 144,
315–317. [PubMed]
19. Binder, L.S. Acute arthropod envenomation. Incidence, clinical features and management. Med. Toxicol. Adv.
Drug Exp. 1989, 4, 163–173. [CrossRef]
20. O’Malley, G.F.; Dart, R.C.; Kuffner, E.F. Successful treatment of latrodectism with antivenin after 90 h. N. Engl.
J. Med. 1999, 340, 657. [CrossRef] [PubMed]
21. Graudins, A. Medical Toxicology; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2004.
22. Hahn, L.; Lewin, N. Goldfrank’s Toxicologic Emergencies; Flomenbaum, N.E., Goldfrank, L.R., Hoffmanm, R.S.,
Howland, M.A., Lewin, N.A., LS, N., Eds.; McGraw-Hill: New York, NY, USA, 2006.
23. Gutierrez, J.M.; Leon, G.; Lomonte, B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin
therapy for envenomation. Clin. Pharmacokinet. 2003, 42, 721–741. [CrossRef] [PubMed]
24. Rivière, G.; Choumet, V.; Audebert, F.; Sabouraud, A.; Debray, M.; Scherrmann, J.-M.; Bon, C. Effect of
antivenom on venom pharmacokinetics in experimentally envenomed rabbits: Toward an optimization of
antivenom therapy. J. Pharmacol. Exp. Ther. 1997, 281, 1–8.
25. Isbister, G.K.; Graudins, A.; White, J.; Warrell, D. Antivenom Treatment in Arachnidism. J. Toxicol.
Clin. Toxicol. 2003, 41, 291–300. [CrossRef] [PubMed]
26. Isbister, G.K. Antivenom efficacy or effectiveness: the Australian experience. Toxicology 2010, 268, 148–154.
[CrossRef] [PubMed]
Toxins 2017, 9, 148 19 of 20
27. Ellis, R.M.; Sprivulis, P.C.; Jelinek, G.A.; Banham, N.D.; Wood, S.V.; Wilkes, G.J.; Siegmund, A.; Roberts, B.L.
A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider
envenoming. Emerg. Med. Australas. 2005, 17, 152–156. [CrossRef] [PubMed]
28. Stanford, C.; Bush, S.; Clark, R.; Arnold, T.; Haynes, J.; Holstege, C.; Bogdan, G.; Garcia, W.; Smith, J.;
Dart, R. A new F(ab)2 antivenom for widow spider envenomation (Latrodectism). In Clinical Toxicology;
Informa Healthcare: New York, NY, USA, 2007.
29. Isbister, G.K. Safety of i.v. administration of redback spider antivenom. Intern. Med. J. 2007, 37, 820–822.
[PubMed]
30. Graudins, A.; Padula, M.; Broady, K.; Nicholson, G.M. Red-back spider (Latrodectus hasselti) antivenom
prevents the toxicity of widow spider venoms. Ann. Emerg. Med. 2001, 37, 154–160. [CrossRef] [PubMed]
31. Daly, F.F.S.; Daly, F.; Hill, R.E.; Bogdan, G.M.; Dart, R.C. Neutralization of Latrodectus mactans and L. hesperus
Venom by Redback Spider (L. hasseltii) Antivenom. J. Toxicol. Clin. Toxicol. 2001, 39, 119–123. [CrossRef]
[PubMed]
32. Jelinek, G.A. Widow spider envenomation (latrodectism): A worldwide problem. Wilderness Environ. Med.
1997, 8, 226–231. [CrossRef]
33. Hoyte, C.O.; Cushing, T.A.; Heard, K.J. Anaphylaxis to black widow spider antivenom. Am. J. Emerg. Med.
2012, 30, 836.e1-2. [CrossRef] [PubMed]
34. Murphy, C.M.; Hong, J.J.; Beuhler, M.C. Anaphylaxis with Latrodectus Antivenin Resulting in Cardiac Arrest.
J. Med. Toxicol. 2011, 7, 317–321. [CrossRef] [PubMed]
35. Wiener, S. Red back spider bite in Australia: An analysis of 167 cases. Med. J. Aust. 1961, 48, 44–49. [PubMed]
36. Keegan, H.L. Effectiveness of Latrodectus tredecimguttatus antivenin in protecting laboratory mice against
effects of intraperitoneal injections of Latrodectus mactans venom. Am. J. Trop. Med. Hyg. 1955, 4, 762–764.
[PubMed]
37. Sutherland, S.K.; Trinca, J.C. Survey of 2144 cases of red-back spider bites: Australia and New Zealand,
1963–1976. Med. J. Aust. 1978, 2, 620–623. [PubMed]
38. Jelinek, G.A.; Banham, N.D.; Dunjey, S.J. Red-back spider-bites at Fremantle Hospital, 1982–1987.
Med. J. Aust. 1989, 150, 693–695. [PubMed]
39. Mead, H.J.; Jelinek, G.A. Red-back spider bites to Perth children, 1979-1988. J. Paediatr. Child Health 1993, 29,
305–308. [CrossRef] [PubMed]
40. Anderson, P. Spider bites and scorpion stings. In Conn’s Current Therapy; Rakel, R., Ed.; W.B. Saunders:
Philadelphia, PA, USA, 1988; pp. 1000–1002.
41. Kunkel, D. Arthropod envenomations. Emerg. Med. Clin. N. Am. 1984, 2, 579–586.
42. Rees, R.S.; Campbell, D. Spider bites. In Management of Wilderness and Environmental Emergencies; Auerbach, P.,
Geehr, E., Eds.; CV Mosby Company: St. Louis, MO, USA, 1989; pp. 548–549.
43. Sutherland, S. Treatment of arachnid poisoning in Australia. Aust. Fam. Physician 1996, 5, 305–312.
44. Mollison, L.; Liew, D.; McDermott, R.; Hatch, F. Red-back spider envenomation in the red centre of Australia.
Med. J. Aust. 1994, 161, 704–705.
45. Dzelalija, B.; Medic, A. Latrodectus bites in Northern Dalmatia, Croatia: Clinical, laboratory, epidemiological,
and therapeutical aspects. Croatian Med. J. 2003, 44, 135–138.
46. Trethewy, C.E.; Bolisetty, S.; Wheaton, G. Red-back spider envenomation in children in Central Australia.
Emerg. Med. (Fremantle, W.A.) 2003, 15, 170–175. [CrossRef]
47. Byrne, G.C.; Pemberton, P.J. Red-back spider (Latrodectus mactans hasselti) envenomation in a neonate.
Med. J. Aust. 1983, 2, 665–666. [PubMed]
48. Nordt, S.P.; Lee, A.; Sasaki, K.; Clark, R.; Cantrell, F.L. Retrospective review of black widow antivenom use.
Clin. Toxicol. 2010, 48, 627.
49. Basanou, E.; Kalostou, A.; Sofidiotou, V.; Fountas, K.; Kalantzopoulos, D.; Papathanassiou, V.; Neou, P.
Treatment of black widow spider (Latrodectus mactans) envenomation: A review of 53 cases. Clin. Toxicol.
2015, 53, 281.
50. Fatovich, D.M.; Dunjey, S.J.; Constantine, C.J.; Hirsch, R.L. Successful treatment of red-back spider bite using
a Bier’s block technique. Med. J. Aust. 1999, 170, 342–343. [PubMed]
51. Isbister, G.K.; O’Leary, M.; Miller, M.; Brown, S.G.A.; Ramasamy, S.; James, R.; Schneider, J.S. A comparison
of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow)
spider antivenom. Br. J. Clin. Pharmacol. 2008, 65, 139–143. [CrossRef] [PubMed]
Toxins 2017, 9, 148 20 of 20
52. Dart, R.; Heard, K.; Bush, S.; Arnold, T.; Sutter, M.; Campagne, D.; Holstege, C.; Seifert, S.; Quan, D.;
Borron, S.W. A Phase III Clinical Trial of Analatro (R)[Antivenin Latrodectus (Black Widow) Equine Immune
F(ab’)2] in Patients with Systemic Latrodectism. In Clinical Toxicology; Taylor & Francis Ltd.: Abingdon, UK, 2016.
53. Dart, R.C.; Bogdan, G.; Heard, K.; Bucher, B.B.; Garcia-Ubbelohde, W.; Bush, S.; Arnold, T.; Clark, R.C.;
Hendey, G.W.; Holstege, C.; et al. A randomized, double-blind, placebo-controlled trial of a highly purified
equine F(ab)2 antibody black widow spider antivenom. Ann. Emerg. Med. 2013, 61, 458–467. [CrossRef]
[PubMed]
54. Isbister, G.K.; Page, C.B.; Buckley, N.A.; Fatovich, D.M.; Pascu, O.; MacDonald, S.P.; Calver, L.A.; Brown, S.G.
Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: The second Redback
Antivenom Evaluation (RAVE-II) study. Ann. Emerg. Med. 2014, 64, 620–628. [CrossRef] [PubMed]
55. Loten, C.; Stokes, B.; Worsley, D.; Seymour, J.E.; Jiang, S.; Isbister, G.K. A randomised controlled trial of hot
water (45 ◦C) immersion versus ice packs for pain relief in bluebottle stings. Med. J. Aust. 2006, 184, 329–333.
[PubMed]
56. Berthier, F.; Potel, G.; Leconte, P.; Touze, M.-D.; Baron, D. Comparative study of methods of measuring acute
pain intensity in an ED. Am. J. Emerg. Med. 1998, 16, 132–136. [CrossRef]
57. Bijur, P.E.; Latimer, C.T.; Gallagher, E.J. Validation of a verbally administered numerical rating scale of acute
pain for use in the emergency department. Acad. Emerg. Med. 2003, 10, 390–392. [CrossRef] [PubMed]
58. Ferreira-Valente, M.A.; Pais-Ribeiro, J.L.; Jensen, M.P. Validity of four pain intensity rating scales. Pain 2011,
152, 2399–2404. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
